Fate Therapeutics Inc Announces Closing Of Initial Public Offering And Exercise Of Option To Purchase Additional Shares
Fate Therapeutics Inc announced the closing of its previously announced initial public offering of 7,666,667 shares of its common stock at a public offering price of $6.00 per share, including 1,000,000 shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares. Aggregate net proceeds to the Company, after deducting underwriting discounts and commissions and other estimated offering expenses, will be approximately $40.4 million. Cowen and Company, LLC and BMO Capital Markets Corp. acted as joint book-running managers for the offering. Wedbush Securities Inc. acted as a co-manager.
Latest Developments for Fate Therapeutics Inc
Latest Key Developments in Biotechnology
- Share this
- Digg this